X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs WOCKHARDT LTD. - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA WOCKHARDT LTD. SANOFI INDIA/
WOCKHARDT LTD.
 
P/E (TTM) x 38.3 -18.6 - View Chart
P/BV x 7.2 2.0 366.0% View Chart
Dividend Yield % 0.5 0.0 26,895.6%  

Financials

 SANOFI INDIA   WOCKHARDT LTD.
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
WOCKHARDT LTD.
Mar-18
SANOFI INDIA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs4,9451,012 488.6%   
Low Rs3,901532 734.0%   
Sales per share (Unadj.) Rs1,081.8355.9 304.0%  
Earnings per share (Unadj.) Rs141.6-60.3 -234.8%  
Cash flow per share (Unadj.) Rs185.9-46.8 -397.6%  
Dividends per share (Unadj.) Rs33.000.01 330,000.0%  
Dividend yield (eoy) %0.70 57,580.3%  
Book value per share (Unadj.) Rs868.8257.8 337.0%  
Shares outstanding (eoy) m23.03110.63 20.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.12.2 188.5%   
Avg P/E ratio x31.2-12.8 -244.0%  
P/CF ratio (eoy) x23.8-16.5 -144.1%  
Price / Book Value ratio x5.13.0 170.1%  
Dividend payout %23.30 -140,522.4%   
Avg Mkt Cap Rs m101,86285,379 119.3%   
No. of employees `0003.26.3 51.8%   
Total wages/salary Rs m3,6859,371 39.3%   
Avg. sales/employee Rs Th7,691.96,295.0 122.2%   
Avg. wages/employee Rs Th1,137.71,498.3 75.9%   
Avg. net profit/employee Rs Th1,006.5-1,066.3 -94.4%   
INCOME DATA
Net Sales Rs m24,91439,369 63.3%  
Other income Rs m8071,202 67.1%   
Total revenues Rs m25,72140,571 63.4%   
Gross profit Rs m5,37218 29,355.2%  
Depreciation Rs m1,0221,495 68.3%   
Interest Rs m112,555 0.4%   
Profit before tax Rs m5,146-2,830 -181.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,886257 733.9%   
Profit after tax Rs m3,260-6,669 -48.9%  
Gross profit margin %21.60 46,387.0%  
Effective tax rate %36.6-9.1 -403.5%   
Net profit margin %13.1-16.9 -77.3%  
BALANCE SHEET DATA
Current assets Rs m14,43233,796 42.7%   
Current liabilities Rs m6,01026,917 22.3%   
Net working cap to sales %33.817.5 193.5%  
Current ratio x2.41.3 191.3%  
Inventory Days Days6179 76.7%  
Debtors Days Days2889 31.9%  
Net fixed assets Rs m7,99139,664 20.1%   
Share capital Rs m230553 41.6%   
"Free" reserves Rs m19,77827,968 70.7%   
Net worth Rs m20,00828,522 70.2%   
Long term debt Rs m021,731 0.0%   
Total assets Rs m27,77081,620 34.0%  
Interest coverage x468.8-0.1 -436,033.3%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x0.90.5 186.0%   
Return on assets %11.8-5.0 -233.7%  
Return on equity %16.3-23.4 -69.7%  
Return on capital %25.8-7.7 -335.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6,3069,807 64.3%   
Fx outflow Rs m5,2571,789 293.9%   
Net fx Rs m1,0498,019 13.1%   
CASH FLOW
From Operations Rs m4,351684 635.7%  
From Investments Rs m-7876,302 -12.5%  
From Financial Activity Rs m-1,884-7,695 24.5%  
Net Cashflow Rs m1,680-664 -253.0%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 2.3 626.1%  
FIIs % 14.6 7.7 189.6%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.5 15.4 68.2%  
Shareholders   15,184 67,757 22.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  ELDER PHARMA  GSK PHARMA  PANACEA BIOTECH  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 150 Points Higher; Banking Stocks Witness Buying(Closing)

Indian share markets continued their momentum and ended the day on a positive note. Gains were largely seen in the banking sector, consumer durables sector and realty sector.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Dec 13, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS